The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10491 malaria professionals are enjoying the free benefits of MalariaWorld today

vaccine trial

Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02(A) vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants

June 26, 2020 - 15:25 -- Open Access
Ouattara A, Niangaly A, Silva JC, et al.
Vaccine. 2020 Jun 19:S0264-410X(20)30821-5

To prevent premature dismissal of promising vaccine programs, it is critical to determine if lack of efficacy in the field is due to allele specific-efficacy, rather than to the lack of immunogenicity of the candidate antigen. Here we use samples collected during a field trial of the AMA1-based FMP2.1/AS02A malaria vaccine, which incorporates the AMA1 variant encoded by the reference Plasmodium falciparum 3D7 strain, to assess the usefulness of epitope-based sieve analysis for the detection of vaccine-induced allele-specific immune responses.

The history of the RTS,S/AS01 malaria vaccine trial

April 27, 2020 - 13:59 -- Open Access
Keating C
Lancet. 2020 Apr 25;395(10233):1336-1337

In 1949, an international congress on malaria coincided with the publication of Mark F Boyd's massive two-volume work on the science of malariology. Placing the tomes on the rostrum, Paul F Russell announced to the delegates, “I present you these volumes as tombstones on the grave of malaria.

Subscribe to RSS - vaccine trial